177 related articles for article (PubMed ID: 34072371)
1. NR4A1 Ligands as Potent Inhibitors of Breast Cancer Cell and Tumor Growth.
Karki K; Mohankumar K; Schoeller A; Martin G; Shrestha R; Safe S
Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34072371
[TBL] [Abstract][Full Text] [Related]
2. Potent inhibition of breast cancer by bis-indole-derived nuclear receptor 4A1 (NR4A1) antagonists.
Hedrick E; Li X; Cheng Y; Lacey A; Mohankumar K; Zarei M; Safe S
Breast Cancer Res Treat; 2019 Aug; 177(1):29-40. PubMed ID: 31119568
[TBL] [Abstract][Full Text] [Related]
3. Nuclear receptor 4A1 as a drug target for breast cancer chemotherapy.
Hedrick E; Lee SO; Doddapaneni R; Singh M; Safe S
Endocr Relat Cancer; 2015 Oct; 22(5):831-40. PubMed ID: 26229035
[TBL] [Abstract][Full Text] [Related]
4. Bis-Indole Derivatives as Dual Nuclear Receptor 4A1 (NR4A1) and NR4A2 Ligands.
Upadhyay S; Hailemariam AE; Mariyam F; Hafiz Z; Martin G; Kothari J; Farkas E; Sivaram G; Bell L; Tjalkens R; Safe S
Biomolecules; 2024 Feb; 14(3):. PubMed ID: 38540704
[TBL] [Abstract][Full Text] [Related]
5. Flavonoids kaempferol and quercetin are nuclear receptor 4A1 (NR4A1, Nur77) ligands and inhibit rhabdomyosarcoma cell and tumor growth.
Shrestha R; Mohankumar K; Martin G; Hailemariam A; Lee SO; Jin UH; Burghardt R; Safe S
J Exp Clin Cancer Res; 2021 Dec; 40(1):392. PubMed ID: 34906197
[TBL] [Abstract][Full Text] [Related]
6. Nuclear receptor 4A1 (NR4A1) antagonists induce ROS-dependent inhibition of mTOR signaling in endometrial cancer.
Mohankumar K; Li X; Sridharan S; Karki K; Safe S
Gynecol Oncol; 2019 Jul; 154(1):218-227. PubMed ID: 31053403
[TBL] [Abstract][Full Text] [Related]
7. Nuclear receptor 4A1 (NR4A1) antagonists target paraspeckle component 1 (PSPC1) in cancer cells.
Mohankumar K; Shrestha R; Safe S
Mol Carcinog; 2022 Jan; 61(1):73-84. PubMed ID: 34699643
[TBL] [Abstract][Full Text] [Related]
8. The Histone Methyltransferase Gene G9A Is Regulated by Nuclear Receptor 4A1 in Alveolar Rhabdomyosarcoma Cells.
Shrestha R; Mohankumar K; Jin UH; Martin G; Safe S
Mol Cancer Ther; 2021 Mar; 20(3):612-622. PubMed ID: 33277444
[TBL] [Abstract][Full Text] [Related]
9.
Zhang L; Martin G; Mohankumar K; Hampton JT; Liu WR; Safe S
Mol Pharmacol; 2022 Jun; 102(2):80-91. PubMed ID: 35680166
[TBL] [Abstract][Full Text] [Related]
10. Bis-Indole-Derived Nuclear Receptor 4A1 (NR4A1, Nur77) Ligands as Inhibitors of Endometriosis.
Mohankumar K; Li X; Sung N; Cho YJ; Han SJ; Safe S
Endocrinology; 2020 Apr; 161(4):. PubMed ID: 32099996
[TBL] [Abstract][Full Text] [Related]
11. Nuclear receptor 4A1 (NR4A1) as a drug target for treating rhabdomyosarcoma (RMS).
Lacey A; Hedrick E; Li X; Patel K; Doddapaneni R; Singh M; Safe S
Oncotarget; 2016 May; 7(21):31257-69. PubMed ID: 27144436
[TBL] [Abstract][Full Text] [Related]
12. The nuclear orphan receptor NR4A1 regulates β1-integrin expression in pancreatic and colon cancer cells and can be targeted by NR4A1 antagonists.
Hedrick E; Lee SO; Safe S
Mol Carcinog; 2017 Sep; 56(9):2066-2075. PubMed ID: 28418095
[TBL] [Abstract][Full Text] [Related]
13. Nuclear Receptor 4A1 (NR4A1) as a Drug Target for Renal Cell Adenocarcinoma.
Hedrick E; Lee SO; Kim G; Abdelrahim M; Jin UH; Safe S; Abudayyeh A
PLoS One; 2015; 10(6):e0128308. PubMed ID: 26035713
[TBL] [Abstract][Full Text] [Related]
14. NR4A1 Antagonists Inhibit β1-Integrin-Dependent Breast Cancer Cell Migration.
Hedrick E; Lee SO; Doddapaneni R; Singh M; Safe S
Mol Cell Biol; 2016 May; 36(9):1383-94. PubMed ID: 26929200
[TBL] [Abstract][Full Text] [Related]
15. Bis-indole-derived NR4A1 antagonists inhibit colon tumor and splenic growth and T-cell exhaustion.
Mohankumar K; Wright G; Kumaravel S; Shrestha R; Zhang L; Abdelrahim M; Chapkin RS; Safe S
Cancer Immunol Immunother; 2023 Dec; 72(12):3985-3999. PubMed ID: 37847301
[TBL] [Abstract][Full Text] [Related]
16. A Bis-Indole-Derived NR4A1 Antagonist Induces PD-L1 Degradation and Enhances Antitumor Immunity.
Karki K; Wright GA; Mohankumar K; Jin UH; Zhang XH; Safe S
Cancer Res; 2020 Mar; 80(5):1011-1023. PubMed ID: 31911554
[TBL] [Abstract][Full Text] [Related]
17. Orphan nuclear receptor 4A1 (NR4A1) and novel ligands.
Safe S; Shrestha R; Mohankumar K
Essays Biochem; 2021 Dec; 65(6):877-886. PubMed ID: 34096590
[TBL] [Abstract][Full Text] [Related]
18. Targeting NR4A1 (TR3) in cancer cells and tumors.
Lee SO; Li X; Khan S; Safe S
Expert Opin Ther Targets; 2011 Feb; 15(2):195-206. PubMed ID: 21204731
[TBL] [Abstract][Full Text] [Related]
19. The Paradoxical Roles of Orphan Nuclear Receptor 4A (NR4A) in Cancer.
Safe S; Karki K
Mol Cancer Res; 2021 Feb; 19(2):180-191. PubMed ID: 33106376
[TBL] [Abstract][Full Text] [Related]
20. Bis-indole derived nuclear receptor 4A1 (NR4A1) antagonists inhibit TGFβ-induced invasion of embryonal rhabdomyosarcoma cells.
Shrestha R; Mohankumar K; Safe S
Am J Cancer Res; 2020; 10(8):2495-2509. PubMed ID: 32905449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
